Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer
Evaxion Biotech A/S (NASDAQ:EVAX) has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. We currently have two product candidates in the DNA technology platform, EVX-02, and EVX-03. Based on preclinical results, the company has decided to move EVX-03…
Benzinga ·
Benzinga
